Livzon Pharmaceutical Group Inc. (Livzon Pharma) filed its Monthly Return for Equity Issuer for the period ended 30 June 2026, indicating a stable capital structure with no movements in either authorised or issued share capital during the month.

Authorised / Registered Share Capital • Total authorised share capital remained unchanged at RMB 887.91 million, split between:  – H shares: 299.81 million ordinary shares at RMB 1 par value each.  – A shares: 588.10 million ordinary shares at RMB 1 par value each.

Issued Share Capital and Treasury Shares • Issued H shares: 299.81 million; treasury shares: zero. • Issued A shares: 588.10 million; treasury shares: zero. • No increases, decreases, repurchases or cancellations were recorded in either share class during June.

Public-Float Status • Livzon Pharma confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 5% for PRC issuers with H-share listings as of 30 June 2026.

Capital-Raising Instruments • The company reported no outstanding or new share options, warrants, convertible securities, or other equity-linked instruments. • No other agreements or arrangements to issue shares were disclosed for the month.

Regulatory Compliance • The filing, signed by Company Secretary Liu Ning on 2 July 2026, affirms that all listing-rule and legal obligations related to previously issued securities have been satisfied.

The absence of share-count changes and the confirmation of sufficient public float underscore Livzon Pharma’s steady equity position as of the end of June 2026.